NCT05100862 2026-03-18
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
Clinical Trials
13 trialsNCT06191744 2026-03-03
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT05929222 2025-12-24
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Phase 3 Recruiting
NCT06108232 2025-12-19
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05326308 2025-09-23
ARIADNE
iOMEDICO AG
Recruiting
NCT07126678 2025-08-17
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Recruiting
NCT05653271 2025-08-11
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech, Inc.
Phase 1 Recruiting
NCT02393157 2025-08-08
O-ICE
New York Medical College
Phase 2 Recruiting
NCT06959732 2025-05-07
Zanubrutinib Combined With G-CVP in Previously Untreated FL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT04450173 2025-04-24
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
University of California, Davis
Phase 2 Recruiting
NCT06284122 2024-10-15
MorningLyte
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT05848765 2023-11-29
REFRACT
University of Birmingham
Phase 2 Recruiting
NCT05899621 2023-06-12
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
Ruijin Hospital
Recruiting